首页工具

搜索结果

Search Results for " preceding "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T7100	PLX5622 PLX-5622	c-Fms; CSF-1R	Tyrosine Kinase/Adaptors
	PLX5622 是一种选择性的、高效的、能透过血脑屏障的、口服具有活性的 CSF1R 抑制剂 (IC50= 0.016 µM;Ki= 5.9 nM)，具有较好的药理学特性，可用于病程发展前和过程中，扩大的和特异性的小胶质细胞的消除。
T68474	RWJ-58643 HCl
	RWJ 58643 is a reversible beta-tryptase and trypsin inhibitor. Low-dose RWJ-58643 (100 microg) and budesonide (200 microg) significantly reduced symptoms, eosinophils and levels of IL-5 following NAC. However, higher doses of RWJ-58643 (300 and 600 microg) caused a late eosinophilia and preceding increases in IL-5 compared with placebo.
T70527	DAT-230
	DAT-230 is a promising microtubule inhibitor that has great potential for the treatment of fibrosarcoma in vitro and in vivo. DAT-230 exhibited potent anti-proliferative activity against various cancer cells. DAT-230 -treatment in HT-1080 cells resulted in microtubule de-polymerization and G2/M phase arrest preceding apoptosis. Phosphor-cdc2 (thr14/tyr15) reduction, cyclin B1 accumulation and aberrant spindles denoted the cyclin B1-cdc2 complex active and M phase arrest in HT-1080 cells treated ...
T12505	PLX5622 hemifumarate	c-Fms	Tyrosine Kinase/Adaptors
	PLX5622 hemifumarate 是高度选择性的、能透过血脑屏障的、具有口服活性的 CSF1R 抑制剂，IC50值为 0.016 μM，Ki 值为 5.9 nM，可用于病程发展前和过程中，扩大和特异性的小胶质细胞的消除。PLX5622 hemifumarate 具有较理想的药代动力学特性。